Press release
Royalty Pharma Reports First Quarter 2025 Results
Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025
About this update from Royalty Pharma Plc
[{"type":"text","content":"Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Guided by our dynamic capital allocation framework, we repurchased over $700 million of our Class A ordinary shares given our attractive outlook, we expanded our development-stage portfolio with an R&D funding partnership with Biogen and we again increased our quarterly dividend. Looking ahead, we have strong fundamental tailwinds underpinning our business with a robust deal pipeline and we remain on track to acquire our external manager in the second quarter. We plan to share further details on our attractive long-term outlook at our upcoming Investor Day in September.” Double-digit growth in Royalty Receipts and Portfolio Receipts Royalty Receipts grew 12% to $788 million, primarily driven by strong performance from the cystic fibrosis franchise, Trelegy and Xtandi.Portfolio Receipts increased by 17% to $839 million. Significant repurchase activity under recently announced $3 billion authorization Repurchased 23 million Class A ordinary shares for $723 million guided by dynamic capital allocation framework.Capital Deployment of $101 million; entered into Phase 3 R&D funding collaboration for Biogen’s litifilimab.Increased quarterly dividend by approximately 5%. Positive clinical and regulatory updates across royalty portfolio Johnson & Johnson’s Tremfya received FDA and EC approval in Crohn’s disease, EC approval in ulcerative colitis.Positive Phase 3 results for Emalex’s ecopipam in Tourette syndrome.Roche to initiate a Phase 3 program for trontinemab in Alzheimer’s disease later this year. Raised financial guidance for full year 2025 (excludes contribution from future transactions) Royalty Pharma expects 2025 Portfolio Receipts to be between $2,975 million and $3,125 million, r...